Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 25 clinical trials
A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis

This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and pharmacokinetics of a higher dose of ocrelizumab per intravenous (IV) infusion

brain mri
relapsing multiple sclerosis
methylprednisolone
MRI
ocrelizumab
  • 4 views
  • 18 Sep, 2022
  • 28 locations
A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and pharmacokinetics of a higher dose of ocrelizumab per intravenous (IV) infusion

brain mri
methylprednisolone
oligoclonal bands
MRI
disease or disorder
  • 3 views
  • 21 Sep, 2022
  • 145 locations
A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis (Operetta 2)

This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged

MRI
fingolimod
ocrelizumab
  • 0 views
  • 17 Sep, 2022
  • 34 locations
LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB (CONSONANCE EX)

The study duration of 4 years was considered to be sufficient to show a reliable and relevant effect of ocrelizumab on disability progression in the main study (CONSONANCE). However, given the

ocrelizumab
  • 0 views
  • 28 Jul, 2022
  • 2 locations
Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing (OVERLORD-MS)

This is a multicenter non-inferiority study, designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients

brain mri
MRI
disease or disorder
rituximab
ocrelizumab
  • 1 views
  • 16 Sep, 2022
  • 12 locations
Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset (IMPACT MS)

Newly diagnosed relapsing multiple sclerosis (MS) and high risk clinically isolated syndrome (CIS) patients will be treated with ocrelizumab at disease onset to see if treatment favorably alters

  • 1 views
  • 12 May, 2022
  • 1 location
Open-Label Multicenter Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis (LEGATO)

ocrelizumab will lead to change of B cell repertoire in LMCE-positive patients.

MRI
secondary progressive multiple sclerosis
ocrelizumab
  • 0 views
  • 17 Sep, 2022
  • 2 locations
Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial

A multicentre controlled phase II trial to compare the efficacy and safety of ocrelizumab or alemtuzumab and autologous Hematopoietic Stem Cell Transplantation (aHSCT). Active relapsing

alemtuzumab
disease or disorder
ocrelizumab
  • 0 views
  • 10 Oct, 2021
  • 2 locations
An Open-Label, Parallel-Group Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

This 2-year study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic (PD) effects of ocrelizumab in children and adolescents ages ≥ 10 to ≤ 18 years with relapsing

brain mri
relapsing multiple sclerosis
disease or disorder
ocrelizumab
  • 9 views
  • 15 Sep, 2022
  • 11 locations
Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis

Phase I / II randomized, single-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of melatonin administration combined with ocrelizumab in patients with Progressive

antioxidants
immunosuppressive agents
ocrelizumab
melatonin
  • 3 views
  • 21 Jul, 2022
  • 3 locations